Oncology (all articles)
NICE Guideline | Thyroid cancer: assessment and management
11 Jan, 2023 | 14:34h | UTCThyroid cancer: assessment and management – National Institute for Health and Care Excellence
Cancer care for people with dementia: literature overview and recommendations for practice and research
11 Jan, 2023 | 14:14h | UTC
Review | Cancer epigenetics in clinical practice
11 Jan, 2023 | 14:15h | UTCCancer epigenetics in clinical practice – CA: A Cancer Journal for Clinicians
Cohort Study | 5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma
11 Jan, 2023 | 14:10h | UTC5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma: an individual patient data meta-analysis from IROCK (the International Radiosurgery Consortium of the Kidney) – The Lancet Oncology (link to abstract – $ for full-text)
Commentary from the author on Twitter (thread – click for more)
🧵1/ Wide adoption of SABR for primary #kidneycancer is limited by long-term data. Online today @TheLancetOncol; 5-yr outcomes in 190 patients. 5% local failure rates, 95% cancer-specific survival. Thanks @ElsevierConnect for 50-day link: #radonc #kcsm https://t.co/kCM8TraJE3
— Shankar Siva (@_ShankarSiva) November 16, 2022
RCT | Adjuvant nab-Paclitaxel + Gemcitabine in resected pancreatic ductal adenocarcinoma
10 Jan, 2023 | 14:13h | UTC
RCT | Neoadjuvant chemotherapy with CAPOX vs. chemoradiation for locally advanced rectal cancer with uninvolved mesorectal fascia
10 Jan, 2023 | 14:09h | UTC
Guideline | Treatment of hypercalcemia of malignancy in adults
9 Jan, 2023 | 14:46h | UTCNews Release: Experts provide first framework for treating hypercalcemia of malignancy in adults – News Medical
ASCO Guideline | Immunotherapy and targeted therapy for advanced gastroesophageal cancer
9 Jan, 2023 | 14:40h | UTC
ASCO Guideline | Immunotherapy and biomarker testing in recurrent and metastatic head and neck cancers
9 Jan, 2023 | 14:41h | UTCNews Release: ASCO Publishes New Guideline on Immunotherapy, Biomarker Testing in Advanced Head and Neck Cancer – ASCO Daily News
The year in cardiovascular medicine 2022: the top 10 papers in cardio-oncology
9 Jan, 2023 | 14:08h | UTC
Commentary on Twitter
The Year in Cardiovascular Medicine 2022 series: the Top 10 papers in Cardio-oncology https://t.co/hfWJ94MmxK@escardio #EHJ #ESCYoung #cardiotwitter @ehj_ed @rladeiraslopes @mayocvonc #cardioonco #CVD @TeresaLpezFdez1 pic.twitter.com/30SNvdvkEV
— European Society of Cardiology Journals (@ESC_Journals) January 2, 2023
Phase 1-2 study | Adagrasib with or without Cetuximab in colorectal cancer with mutated KRAS G12C
9 Jan, 2023 | 14:04h | UTCAdagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C – New England Journal of Medicine (link to abstract – $ for full-text)
News Release: Advanced Colorectal Cancer Treatment Targets KRAS Gene With Drug Combo – Memorial Sloan Kettering Cancer Center
Commentary on Twitter
In heavily pretreated patients with mutant KRAS G12C colorectal cancer, adagrasib induced a response in 19% as single agent and in 46% in combination with cetuximab, an epidermal growth factor receptor antibody. https://t.co/nCoEPeV9oB pic.twitter.com/FCHxU9WCin
— NEJM (@NEJM) December 21, 2022
M-A | Laparoscopic vs. open pancreatoduodenectomy in patients with periampullary tumors
9 Jan, 2023 | 14:02h | UTCLaparoscopic versus Open Pancreatoduodenectomy in Patients with Periampullary Tumors: A Systematic Review and Meta-analysis – Annals of Surgery (link to abstract – $ for full-text)
RCT | The addition of Olanzapine to a triple antiemetic regimen effectively prevents nausea and vomiting during highly emetogenic chemotherapy.
16 Dec, 2022 | 13:32h | UTCRelated:
Review | Human papillomavirus vaccination and cervical cancer risk.
16 Dec, 2022 | 13:26h | UTCHuman papillomavirus vaccination and cervical cancer risk – The BMJ
Review | Advances in diagnosis and treatment of testicular cancer.
16 Dec, 2022 | 13:25h | UTCAdvances in diagnosis and treatment of testicular cancer – The BMJ
Review | Endometrial cancer: molecular classification and future treatments.
16 Dec, 2022 | 13:20h | UTCEndometrial cancer: molecular classification and future treatments – BMJ Medicine
Commentary on Twitter
The latest #review by Bradley Corr and colleagues concludes that the development of molecular analysis combined with novel agents and new drug classes have revolutionised #precisionmedicine for patients with endometrial #cancer. Read now ▶️ https://t.co/TaNgrM2EWl#MedTwitter pic.twitter.com/GexXdLzlQH
— BMJMedicine (@BMJMedicine) December 9, 2022
Perspective | The importance of long-term follow up of participants in clinical trials.
16 Dec, 2022 | 13:13h | UTCThe importance of long-term follow up of participants in clinical trials – British Journal of Cancer
Review | Role of AI and digital pathology for colorectal immuno-oncology.
16 Dec, 2022 | 13:11h | UTCRole of AI and digital pathology for colorectal immuno-oncology – British Journal of Cancer
A comprehensive systematic review of colorectal cancer screening clinical practices guidelines and consensus statements.
16 Dec, 2022 | 13:09h | UTC
RCT | Assessment of spleen-preserving hilar lymphadenectomy for advanced proximal gastric cancer without invasion into the greater curvature.
15 Dec, 2022 | 13:30h | UTCAssessment of Laparoscopic Spleen-Preserving Hilar Lymphadenectomy for Advanced Proximal Gastric Cancer Without Invasion Into the Greater Curvature: A Randomized Clinical Trial – JAMA Surgery (link to abstract – $ for full-text)
See also: Visual Abstract and Video Summary
Post-trial follow-up | Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer.
15 Dec, 2022 | 13:29h | UTCFluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)
Commentary: Dose-Dense Adjuvant Chemotherapy “Optimal” for High-Risk Early Breast Cancer – Cancer Therapy Advisor
Commentary on Twitter
Online first: end-of-study results from the randomised, phase 3 GIM2 trial: #fluorouracil and dose-dense adjuvant #chemotherapy in patients with #early-stage #breastcancer https://t.co/9YD5w9aLY2 pic.twitter.com/RmPdi37sQB
— The Lancet Oncology (@TheLancetOncol) November 10, 2022
Phase 2 RCT | Immediate surgery vs. short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer.
14 Dec, 2022 | 15:01h | UTCNews Release: Chemotherapy before surgery can improve survival rates in pancreatic cancer patients – University of Liverpool
Commentary on Twitter
New research – Ghaneh et al – Immediate surgery vs short-course neoadjuvant gemcitabine + capecitabine, FOLFIRINOX, or chemoradiotherapy in patients w/ borderline resectable #pancreaticcancer (ESPAC5): a randomised phase 2 trialhttps://t.co/9S1hupyKjg#gitwitter #onctwitter pic.twitter.com/g2jQUAhUSJ
— The Lancet Gastroenterology & Hepatology (@LancetGastroHep) December 14, 2022
Podcast | Prostate cancer: screening, advanced testing, and survivorship.
14 Dec, 2022 | 14:48h | UTC#371 Prostate Cancer: Screening, Advanced Testing, and Survivorship – The Curbsiders
RCT | Optimal treatment duration of bevacizumab as front-line therapy for advanced ovarian cancer.
14 Dec, 2022 | 14:44h | UTCOptimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)
Commentary on Twitter
👍 LESS IS MORE – Extra cycles of bevacizumab in frontline maintnenance do not yield improved progression free or overall survival in advanced stage #OvarianCancer
👍 15 months remains standard of care ➡️ https://t.co/nKwehjxnHu #gyncsm pic.twitter.com/9DBInZv1t0— Journal of Clinical Oncology (@JCO_ASCO) December 4, 2022
RCT | Durvalumab with or without Tremelimumab plus chemotherapy for metastatic non–small-cell lung cancer.
14 Dec, 2022 | 14:47h | UTCCommentary: Adding Tremelimumab and Durvalumab to Chemo Improves PFS, OS in mNSCLC – Cancer Therapy Advisor
Commentary on Twitter
🙌 POSEIDON: 1L tremelimumab + durvalumab + chemotherapy significantly improve progression-free and overall survival in stage IV non small cell #LungCancer 👉 https://t.co/d6causVZ4u #JCO #ImmunoOnc #Immunotherapy #LCSM @MLJohnsonMD2 #NSCLC pic.twitter.com/aIkCwSAwFe
— Journal of Clinical Oncology (@JCO_ASCO) December 3, 2022